Teichmann Sarah A. 4

What Happened

• Sarah A. Teichmann, a director of 10x Genomics, was granted 8,829 restricted stock units (RSUs) on 2026-06-04. The filing reports an acquisition type "A" (award/grant) at $0.00 per unit (total $0 reported). Each RSU is a contingent right to receive one share of Class A common stock upon vesting.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-08 (timely).
• Grant amount: 8,829 RSUs; reported acquisition price: $0.00.
• Vesting: 1/4 of the RSUs vest on each quarterly anniversary measured from May 21, 2026, subject to continued service (per footnote).
• Shares owned after the transaction: not disclosed in the filing.
• Transaction code: A = Award/Grant (RSUs). No 10b5-1 or tax-withholding notes were indicated in the provided footnote.

Context

• RSU grants are compensation awards, not open-market purchases or sales. They carry value only if and when they vest and the underlying shares have market value at that time. This grant indicates compensation alignment rather than an immediate buy or sell signal.